HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Jun 22

PMID 37345001

Authors

Yanjun Hou

Hiroaki Nitta

Zaibo Li

Affiliations

Soon will be listed here.

Abstract

Amplification and/or overexpression of human epidermal growth factor receptor 2 (HER2) in breast cancer is associated with an adverse prognosis. The introduction of anti-HER2 targeted therapy has dramatically improved the clinical outcomes of patients with HER2-positive breast cancer. Unfortunately, a significant number of patients eventually relapse and develop distant metastasis. HER2 intratumoral heterogeneity (ITH) has been reported to be associated with poor prognosis in patients with anti-HER2 targeted therapies and was proposed to be a potential mechanism for anti-HER2 resistance. In this review, we described the current definition, common types of HER2 ITH in breast cancer, the challenge in interpretation of HER2 status in cases showing ITH and the clinical applications of anti-HER2 agents in breast cancer showing heterogeneous HER2 expression. Digital image analysis has emerged as an objective and reproducible scoring method and its role in the assessment of HER2 status with ITH remains to be demonstrated.

Citing Articles

The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype.

Turova P, Kushnarev V, Baranov O, Butusova A, Menshikova S, Yong S NPJ Breast Cancer. 2025; 11(1):19.

PMID: 39979291 PMC: 11842814. DOI: 10.1038/s41523-025-00723-0.

Novel Molecular Classification of Breast Cancer with PET Imaging.

Toan N Medicina (Kaunas). 2025; 60(12.

PMID: 39768978 PMC: 11678748. DOI: 10.3390/medicina60122099.

Evaluation of HER2 immunohistochemistry expression in non-standard solid tumors from a Single-Institution Prospective Cohort.

Verma S, Chapman A, Pickard L, Porplycia D, McConkey H, Jarosz P Explor Target Antitumor Ther. 2024; 5(5):1100-1109.

PMID: 39351438 PMC: 11438559. DOI: 10.37349/etat.2024.00265.

The Performance and Clinical Applicability of HER2 Digital Image Analysis in Breast Cancer: A Systematic Review.

Dunenova G, Kalmataeva Z, Kaidarova D, Dauletbaev N, Semenova Y, Mansurova M Cancers (Basel). 2024; 16(15).

PMID: 39123488 PMC: 11311684. DOI: 10.3390/cancers16152761.

Integrating single-cell transcriptomics and machine learning to predict breast cancer prognosis: A study based on natural killer cell-related genes.

Mao J, Liu L, Shen Q, Cen M J Cell Mol Med. 2024; 28(15):e18549.

PMID: 39098994 PMC: 11298315. DOI: 10.1111/jcmm.18549.

References

Cronin K, Harlan L, Dodd K, Abrams J, Ballard-Barbash R . Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 2010; 28(9):963-8. PMC: 5094051. DOI: 10.3109/07357907.2010.496759. View

Gebhart G, Lamberts L, Wimana Z, Garcia C, Emonts P, Ameye L . Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann Oncol. 2015; 27(4):619-24. DOI: 10.1093/annonc/mdv577. View

Farahmand S, Fernandez A, Shabbir Ahmed F, Rimm D, Chuang J, Reisenbichler E . Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer. Mod Pathol. 2021; 35(1):44-51. PMC: 10221954. DOI: 10.1038/s41379-021-00911-w. View

Jiang G, Zhang S, Yazdanparast A, Li M, Pawar A, Liu Y . Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genomics. 2016; 17 Suppl 7:525. PMC: 5001206. DOI: 10.1186/s12864-016-2911-z. View

Dobson L, Conway C, Hanley A, Johnson A, Costello S, OGrady A . Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation. Histopathology. 2010; 57(1):27-38. PMC: 2916223. DOI: 10.1111/j.1365-2559.2010.03577.x. View

Rye I, Trinh A, Saetersdal A, Nebdal D, Lingjaerde O, Almendro V . Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors. Mol Oncol. 2018; 12(11):1838-1855. PMC: 6210052. DOI: 10.1002/1878-0261.12375. View

Abd El-Rehim D, Pinder S, Paish C, Bell J, Rampaul R, Blamey R . Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer. 2004; 91(8):1532-42. PMC: 2410019. DOI: 10.1038/sj.bjc.6602184. View

Brugmann A, Eld M, Lelkaitis G, Nielsen S, Grunkin M, Hansen J . Digital image analysis of membrane connectivity is a robust measure of HER2 immunostains. Breast Cancer Res Treat. 2011; 132(1):41-9. DOI: 10.1007/s10549-011-1514-2. View

Denkert C, Seither F, Schneeweiss A, Link T, Blohmer J, Just M . Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021; 22(8):1151-1161. DOI: 10.1016/S1470-2045(21)00301-6. View

10.

Fleming G, Sill M, Darcy K, McMeekin D, Thigpen J, Adler L . Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2009; 116(1):15-20. PMC: 2804260. DOI: 10.1016/j.ygyno.2009.09.025. View

11.

Yagi S, Wakatsuki T, Yamamoto N, Chin K, Takahari D, Ogura M . Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer. Gastric Cancer. 2018; 22(3):518-525. PMC: 6476840. DOI: 10.1007/s10120-018-0887-x. View

12.

MacNeil I, Burns D, Rich B, Soltani S, Kharbush S, Osterhaus N . New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified. J Cancer Res Clin Oncol. 2020; 146(3):605-619. PMC: 7039866. DOI: 10.1007/s00432-020-03144-7. View

13.

Najjar S, Allison K . Updates on breast biomarkers. Virchows Arch. 2022; 480(1):163-176. DOI: 10.1007/s00428-022-03267-x. View

14.

Zhang H, Katerji H, Turner B, Hicks D . HER2-Low Breast Cancers. Am J Clin Pathol. 2021; 157(3):328-336. DOI: 10.1093/ajcp/aqab117. View

15.

Hurvitz S, Martin M, Jung K, Huang C, Harbeck N, Valero V . Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. J Clin Oncol. 2019; 37(25):2206-2216. PMC: 6774816. DOI: 10.1200/JCO.19.00882. View

16.

Bozkurt K, Ciris I, Baspinar S, Cetin B, Erdemoglu E, Bircan S . The Prognostic Effect of Gene Amplification in High-Grade Endometrial Carcinomas and its Correlation with Protein Overexpression. Int J Surg Pathol. 2022; 31(4):365-374. DOI: 10.1177/10668969221102529. View

17.

Grassini D, Cascardi E, Sarotto I, Annaratone L, Sapino A, Berrino E . Unusual Patterns of HER2 Expression in Breast Cancer: Insights and Perspectives. Pathobiology. 2022; 89(5):278-296. DOI: 10.1159/000524227. View

18.

Ohlschlegel C, Zahel K, Kradolfer D, Hell M, Jochum W . HER2 genetic heterogeneity in breast carcinoma. J Clin Pathol. 2011; 64(12):1112-6. DOI: 10.1136/jclinpath-2011-200265. View

19.

Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31(31):3997-4013. DOI: 10.1200/JCO.2013.50.9984. View

20.

Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T . Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016; 107(7):1039-46. PMC: 4946713. DOI: 10.1111/cas.12966. View